Valuation: Alector, Inc.

Market Cap 275M 236M 221M 202M 381M 26.2B 383M 2.62B 1.01B 13.22B 1.03B 1.01B 43.78B P/E 2026 *
-2.87x
P/E 2027 * -3.53x
Enterprise Value 47.21M 40.52M 38.03M 34.73M 65.55M 4.5B 65.87M 450M 174M 2.27B 177M 173M 7.52B EV / Sales 2026 *
4.3x
EV / Sales 2027 * -0.84x
Free-Float
90.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+4.24%
1 week+1.23%
Current month+62.91%
1 month+66.22%
3 months+12.33%
6 months-3.91%
Current year+57.69%
1 week 2.2
Extreme 2.2
2.52
1 month 1.46
Extreme 1.455
2.52
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
19/08/26 Don

Founder

-2,100,000 1.8915%
09/07/26 Free

Controller/Auditor

20,000 0.0180%
26/02/26 Sell

Controller/Auditor

4,079 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+4.24%+1.23%+4.24%-58.31% 264M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+2.28%+49.95%+91.30% 64.17B
-1.31%-0.50%+7.41%-4.29% 28.65B
+0.40%-4.80%-5.89%+469.55% 27.06B
+0.99%+5.95%+55.58%+14.43% 27.33B
-1.68%+0.33%+36.86%-16.09% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
+1.83%-0.57%+7.19%+515.61% 15.96B
-1.09%+3.14%+46.32%+155.12% 14.05B
Average +0.36%+3.77%+53.21%+169.13% 28.87B
Weighted average by Cap. +0.80%+3.29%+54.97%+153.93%

Financials

2026 *2027 *
Net sales 10.98M 9.42M 8.84M 8.08M 15.24M 1.05B 15.32M 105M 40.55M 528M 41.21M 40.32M 1.75B 26.17M 22.46M 21.08M 19.25M 36.34M 2.5B 36.51M 249M 96.68M 1.26B 98.25M 96.12M 4.17B
Net income -96.86M -83.13M -78.03M -71.27M -134M -9.24B -135M -923M -358M -4.66B -364M -356M -15.44B -98.04M -84.14M -78.98M -72.13M -136M -9.35B -137M -935M -362M -4.72B -368M -360M -15.62B
Net Debt -227M -195M -183M -167M -316M -21.7B -317M -2.17B -840M -10.95B -854M -836M -36.25B -297M -255M -239M -218M -412M -28.3B -414M -2.83B -1.1B -14.28B -1.11B -1.09B -47.3B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26/08/26 $2.460 +4.24% 995,494
25/08/26 $2.360 +2.61% 558,276
24/08/26 $2.300 -2.54% 738,144
21/08/26 $2.360 +4.42% 728,094
20/08/26 $2.260 -7.00% 662,589
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.460USD
Average target price
3.100USD
Spread / Average Target
+26.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock